What Is Retatrutide?

Retatrutide is an investigational triple-hormone-receptor agonist designed to activate GIP, GLP-1, and glucagon receptor pathways. It is not FDA-approved. Retatrutide may be discussed with a licensed provider only where clinically appropriate and legally available.

How It Works

Retatrutide is being studied for combined activity at GIP, GLP-1, and glucagon receptors. GLP-1 and GIP pathways are involved in appetite, insulin response, and metabolic signaling; glucagon receptor activity is being investigated for possible effects on energy expenditure and metabolic regulation. Because it remains investigational, this is not an established treatment mechanism for patients.

What It’s Studied For

Retatrutide has been studied in clinical trials for obesity and metabolic disease, including a phase 2 trial in adults with obesity that evaluated dose-response, efficacy, side effects, and safety over 48 weeks. Long-term safety, approval status, labeling, and final therapeutic role remain under investigation.

How It May Be Used in a Clinician-Supervised Program

If discussed, retatrutide is framed as investigational and provider-discussed. The clinician reviews weight history, metabolic risk, gastrointestinal history, pancreatitis/gallbladder history, cardiovascular status, pregnancy status, current medications, and legal availability. Treatment is never guaranteed and is not equivalent to FDA-approved GLP-1 products.

Preferred Starting Options / Dosing Notes

Many patients begin with a lower starting option so a licensed clinician can evaluate tolerance, medical history, goals, and safety factors before any adjustments are considered. The starting option shown below is informational and reflects available program data, not self-directed dosing instructions. Final medication, dose, frequency, and treatment plan are determined by a licensed clinician.

Safety Considerations

• Safety profile is still being defined; trial-reported concerns are generally consistent with incretin-based therapies, including gastrointestinal effects.
• Long-term and real-world safety are not established.
• FDA has issued warnings about unapproved GLP-1 products sold directly to consumers and falsely labeled as research products.

Some treatments may involve compounded medications when prescribed by a clinician. Compounded medications are not FDA-approved. The FDA does not evaluate compounded medications for safety, effectiveness, or quality before marketing.

Frequently Asked Questions